Record orders, strong growth, but margins must hold amid ramp risks

35.3% YoY, ₹2,462.6 Cr revenue delivered

Delivered 29% OPM, 18.8% NPM (EBITDA margin reasonable; NPM exact match)

Delivered 53.3% PAT growth YoY

QoQ revenue +10.4% only; non-DCR acknowledged as unprofitable utilization play

New orders ₹3,011 Cr this quarter; order mix 58% cells (FY28-FY29) vs 42% modules (H2 FY27) implies timing stagger

Q1 delivered 29% OPM; contingent on cell line ramp (operating leverage), DCR margin hold, transformer accretion

Prior guidance ₹14,010 Cr primarily FY27. New orders ₹3,011 Cr this quarter raised total to ₹15,000 Cr. Modest +7% beat but execution risk remains.

Prior guidance 'stable or improve' and 'industry-leading.' Now quantified as 29-30% (current ₹29% OPM confirmed). No upside upgrade; contingent on DCR mix and cell ramp.

₹1,500 Cr spent Q1 (₹1,250 Cr solar, ₹250 Cr Transcon). On track for ₹6,000+ Cr total if quarterly burn ~₹1.5k Cr. Slight overshoot vs plan but within range.

Prior guidance transformation to higher-margin DCR. Seetharampur module (92% utilization this quarter) live; TOPCon cell ramp starting Sept. On track vs prior roadmap.

New quantified guidance. Q1 Transcon ₹110 Cr (1 month). Implies ₹400-500 Cr annual run-rate; 3x target = ₹1,200-1,500 Cr by FY30. Capacity 16.25 GVA by FY28 (vs 4 GVA now).

US cell JV: 24-30 month timeline post location finalized. Europe: office opening, sales team hiring, tenders from Italy/France starting. New geographic growth levers.

KUSUM B/C overloading 1.2-1.25x blended. Expects 23-24 GW DC (6-8 GW AC KUSUM + 12-13 GW rooftop) in 9M. Government deadline March '27 drives execution.

Contracts signed pre-cellline ramp. Moving progressively to more DCR modules vs cells. 10 GW cell + 11 GW module means limited cells for external sale post-ramp.

40-45% order book for FY28. DCR sold out, selling only FY28 now. Non-DCR influx temporary due to Dec deadline rush.

Yes, protect 29-30% margins. Cell line and transformer capacity give operating leverage. Order book has similar margins as delivered.

No, C&I players blocking capacity for FY28 today, not deferring. Signed FY28 orders confirm blockings. Strong demand throughout FY27-FY28.

Treble over 3 years. Initial ramp slow (certification, orders). Revenue outlook slightly south of ₹1,300-1,400 Cr near-term. Margins 15% EBITDA, 8-10% PAT target (vs 27%/17% current Transcon).

First revenue Sept. 50-60% util November. 70% by March. Will take time to ramp.

Non-DCR not profitable, but ordered to avoid idle capacity. Slight margin improvement for non-DCR this Q as everyone rushes for Dec connect. Long-term, DCR focus.

Depreciation ₹240-250 Cr/quarter by Q3-Q4 (vs lower Q1). Finance expenses modest increase as bulk of capex equity-funded.

Stable for both DCR and cells. Surya Ghar 24-24.5 ¢/W, KUSUM ~22 ¢/W, C&I lower. Order book booked at current prices, no change expected.

Yes, JV already exists. Location finalized soon. 24-30 months timeline. MIP makes it strategically sound.

Europe take-off stage. Opening office, hiring sales team. Italy auction live, France tenders out. Expect Germany/EU tenders excluding China modules. 2-3 year horizon for meaningful contribution.

Consolidation inevitable. Scale, vertical integration, technology are 3 key levers. Backward integration (cell, ingot-wafer) and 10+ GW scale create cost/pricing power moat.

40-45% order book for FY28 per management. Implies FY27 ~60-65% (₹9-10k Cr range). But no explicit FY27 revenue target stated.

Aggressive ramp. 50-60% Nov, 70% March implies ~5 GW output in H2 FY27 vs ~2-3 GW H1 base. Execution risk on yield, demand absorption.

Contingent on DCR mix (high-margin), non-DCR fade, cell line ramp (operating leverage). No upside upgrade; protection mode. Q1 delivered 30.3% EBITDA per call.

Transcon Q1 at 27% EBITDA, 17% PAT (well above industry). Ramp-up may compress margins; confidence medium on sustainability.

₹1,500 Cr Q1 spend implies ₹6k Cr annualized run-rate if consistent. Slightly above plan but on track. Solar, transformer, BESS funding.

7 GW TOPCon cell line (Sept revenue, 70% by Mar) and new module/transformer capacity. Yield, automation, staffing delays could slip timelines. 70% utilization target aggressive.

Non-DCR unprofitable (30 GW demand vs 250 GW capacity). DCR sold out but no guarantee of 29-30% margin hold post-ramp if supply increases. Management not upgrading margin guidance despite capex.

Steep duck curve, solar capacity growth outpacing grid/battery infrastructure. Risk of demand curtailment or lower tariff realization if grid can't absorb capacity.

Small non-integrated cell/module players exiting. Favors Premier (scale, integration, tech) but accelerated consolidation could create fewer, larger competitors (Chinese entrants, other Indian scale-ups).

US cell JV: 24-30 month timeline (2028-2029 start). Europe expansion just beginning (office, sales team). Low near-term revenue but high strategic importance.